Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 18,106,000 | 12,059,000 | 3,057,000 | 2,574,000 | 2,789,059 |
| Depreciation Amortization | 1,098,000 | 1,050,000 | 345,000 | 278,000 | 302,232 |
| Income taxes - deferred | -393,000 | -236,000 | -98,000 | -39,000 | 64,061 |
| Accounts receivable | -1,397,000 | -2,578,000 | -315,000 | 198,000 | -375,736 |
| Accounts payable and accrued liabilities | 226,000 | -289,000 | -98,000 | 117,000 | 428,944 |
| Other Working Capital | 1,495,000 | -518,000 | -562,000 | 108,000 | 211,853 |
| Other Operating Activity | 2,115,000 | 3,330,000 | 776,000 | -41,000 | 218,597 |
| Operating Cash Flow | $21,250,000 | $12,818,000 | $3,105,000 | $3,195,000 | $3,639,010 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -11,728,000 | -1,248,000 | 315,000 | -672,000 | 4,310,357 |
| PPE Investments | -747,000 | -557,000 | -190,000 | -397,000 | -131,904 |
| Net Acquisitions | N/A | N/A | -379,000 | -10,752,000 | -588,608 |
| Purchase Of Investment | N/A | -18,000 | N/A | -25,000 | 0 |
| Investing Cash Flow | $-12,475,000 | $-1,823,000 | $-254,000 | $-11,846,000 | $3,589,845 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 10,686,000 | 10,475,000 | 2,774,000 | 2,358,000 | 4,696,850 |
| Debt Repayment | -997,000 | -4,805,000 | -4,440,000 | -1,839,000 | -687,697 |
| Common Stock Issued | 319,000 | 331,000 | 313,000 | 466,000 | 211,737 |
| Common Stock Repurchased | -10,002,000 | -5,349,000 | -582,000 | -667,000 | -2,383,132 |
| Dividend Paid | -1,874,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -4,016,000 | -3,677,000 | -609,000 | 245,000 | -74,189 |
| Financing Cash Flow | $-5,884,000 | $-3,025,000 | $-2,544,000 | $563,000 | $1,763,569 |
| Exchange Rate Effect | -67,000 | -56,000 | 2,000 | 8,000 | -16,526 |
| Beginning Cash Position | 10,027,000 | 2,113,000 | 1,804,000 | 9,884,000 | 907,879 |
| End Cash Position | 12,851,000 | 10,027,000 | 2,113,000 | 1,804,000 | 9,883,777 |
| Net Cash Flow | $2,824,000 | $7,914,000 | $309,000 | $-8,080,000 | $8,975,898 |
| Free Cash Flow | |||||
| Operating Cash Flow | 21,250,000 | 12,818,000 | 3,105,000 | 3,195,000 | 3,639,010 |
| Capital Expenditure | -747,000 | -557,000 | -190,000 | -397,000 | -131,904 |
| Free Cash Flow | 20,503,000 | 12,261,000 | 2,915,000 | 2,798,000 | 3,507,106 |